SCHEMBL5899339

SCHEMBL5899339

O=C(C=C(O)c1nncs1)c1ccc(Cc2ccc(F)cc2)o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.34
POLB P06746 2/20 0.34
HPGD P15428 2/20 0.33
RAB9A P51151 2/20 0.33
NPC1 O15118 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 2/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
TP53 P04637 3/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
LMNA P02545 4/20 0.32
MAPT P10636 3/20 0.32
RECQL P46063 1/20 0.32
MAOA P21397 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673404 0.81 RAB9A (0.44) CES1HPGDRAB9ANPC1MEN1
SCHEMBL3216621 0.78 CYP1A2 (0.41) POLBHPGDRAB9ANPC1MEN1
SCHEMBL4673718 0.78 NFE2L2 (0.46) POLBHPGDMEN1ALDH1A1KMT2A
SCHEMBL3218292 0.78 ABL1 (0.44) POLBHPGDRAB9ANPC1MEN1
SCHEMBL5899340 0.78 POLB (0.36) CES1POLBHPGDRAB9ANPC1
SCHEMBL3220721 0.77 L3MBTL1 (0.43) POLBHPGDALDH1A1KMT2ANPSR1
SCHEMBL4673599 0.76 LMNA (0.37) HPGDRAB9ANPC1MEN1ALDH1A1
SCHEMBL4671648 0.76 CES1 (0.34) CES1NPSR1CYP1A2CYP2D6CYP2C9
SCHEMBL755173 0.76 MAPT (0.38) POLBHPGDALDH1A1NPSR1TP53
SCHEMBL755174 0.76 MAPT (0.38) POLBHPGDALDH1A1NPSR1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CES1 445/4885POLB 58/4885HPGD 2816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.